A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Erasmus MC, Erasmus MC - Sophia Children’s Hospital, Oregon Health & Science University, Institut d’Hématologie et d’Oncologie Pédiatrique, Hospices Civils de Lyon, University of Colorado Cancer Center, Northwestern University, Lurie Children's Hospital, Universidade Estadual de Campinas (UNICAMP), Support group for adolescents and children with cancer, Bristol-Myers Squibb (United States), University of Birmingham
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3011917320